Great first day of trade and some solid turnover to get people set at a higher base. Very cheap still even at this price for the potential and ease to market of the end product (reformed Byetta which is produced currently by AstraZeneca!). Outside the top 20 there is only around 10m shares floating about so 30% turnover of that today.
Interesting final part of news indicating that Prof Sinclair attended a round table with NASA who are looking at ways to reduce brain pressure associate with long duration space flight.
Ann: Invex Therapeutics Lists on ASX, page-4
-
- There are more pages in this discussion • 146 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
